Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Early, Oligoarticular Psoriatic Arthritis
NCT03747939Phase 4Completed
- Sponsor
- Amgen
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 4, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Apremilast with Placebo (2 arms). Primary endpoint: Minimal Disease Activity (MDA-Joints) Response at 16 weeks. Started Dec 2018; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03747939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747939.